Treatment schedule of the LPA99 and LPA2005 trials. Ara-C indicates cytarabine; IDA, idarubicin; and MTZ, mitoxantrone. High-risk patients older than 60 years did not receive cytarabine and were treated as intermediate-risk patients.
Sign In or Create an Account